[go: up one dir, main page]

IL144831A0 - USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS - Google Patents

USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS

Info

Publication number
IL144831A0
IL144831A0 IL14483100A IL14483100A IL144831A0 IL 144831 A0 IL144831 A0 IL 144831A0 IL 14483100 A IL14483100 A IL 14483100A IL 14483100 A IL14483100 A IL 14483100A IL 144831 A0 IL144831 A0 IL 144831A0
Authority
IL
Israel
Prior art keywords
pivs
piv
vectors
protect against
disease caused
Prior art date
Application number
IL14483100A
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/458,813 external-priority patent/US7314631B1/en
Priority claimed from US09/459,062 external-priority patent/US7250171B1/en
Application filed by Us Health filed Critical Us Health
Publication of IL144831A0 publication Critical patent/IL144831A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18641—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14483100A 1999-12-10 2000-12-08 USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS IL144831A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17019599P 1999-12-10 1999-12-10
US09/458,813 US7314631B1 (en) 1997-05-23 1999-12-10 Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)
US09/459,062 US7250171B1 (en) 1997-05-23 1999-12-10 Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein
PCT/US2000/033293 WO2001042445A2 (en) 1999-12-10 2000-12-08 USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS

Publications (1)

Publication Number Publication Date
IL144831A0 true IL144831A0 (en) 2002-06-30

Family

ID=27389780

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14483100A IL144831A0 (en) 1999-12-10 2000-12-08 USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS

Country Status (8)

Country Link
EP (1) EP1179054A2 (en)
JP (1) JP4795597B2 (en)
CN (2) CN1347453A (en)
AU (1) AU785148B2 (en)
CA (1) CA2362685A1 (en)
IL (1) IL144831A0 (en)
MX (1) MXPA01008108A (en)
WO (1) WO2001042445A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
JP5503096B2 (en) 2001-01-19 2014-05-28 ヴィロノヴァティブ，ベスローテン ヴェンノートシャップ Virus that causes respiratory tract disease in susceptible mammals
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
CA2467958A1 (en) 2001-11-21 2003-05-30 Brian R. Murphy Recovery of recombinant human parainfluenza virus type 1 (hpivi) from cdna
JP4553589B2 (en) 2002-02-21 2010-09-29 メディミューン，エルエルシー Recombinant parainfluenza virus expression system and vaccine containing heterologous antigen obtained from metapneumovirus
US7081341B2 (en) 2002-07-01 2006-07-25 Wayne State University Methods and compositions for the identification of antibiotics that are not susceptible to antibiotic resistance
JP4549188B2 (en) * 2002-09-18 2010-09-22 アメリカ合衆国 Recombination from cDNA of recombinant human type 2 parainfluenza virus (HPIV2) and use of recombinant HPIV2 in immunogenic compositions to elicit immune responses against PIV and other human pathogens and as vectors
US7704491B2 (en) 2003-02-28 2010-04-27 The United States Of America As Represented By The Department Of Health And Human Services Recombinant human metapneumovirus and its use
US7704720B2 (en) 2003-04-25 2010-04-27 Medimmune, Llc Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
BRPI0411247A (en) 2003-06-09 2006-07-25 Wyeth Corp improved process for recovering non-segmented negative filament rna viruses from cdna
DE102005006388A1 (en) 2005-02-11 2006-08-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Replication-deficient RNA viruses as vaccines
US8293517B2 (en) 2005-05-11 2012-10-23 Wayne State University Methods and compositions for the identification of antibiotics that are not susceptible to antibiotic resistance in Pseudomonas aeruginosa
AU2006243923B2 (en) * 2005-05-11 2011-09-22 Wayne State University Novel targets for the identification of antibiotics that are not susceptible to antibiotic resistance
JP4905649B2 (en) * 2006-03-08 2012-03-28 国立大学法人 長崎大学 Fish vaccine, method for producing the same, and method for preventing fish infection
JP4892296B2 (en) * 2006-08-24 2012-03-07 川崎製薬株式会社 Vaccines for fish edovagerosis and streptococcal disease
US8362203B2 (en) 2009-02-10 2013-01-29 Wayne State University Non-natural peptides as models for the development of antibiotics
MX2012002365A (en) 2009-08-24 2012-07-17 Baylor College Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses.
WO2013112690A1 (en) 2012-01-24 2013-08-01 Universtiy Of Georgia Research Foundation, Inc. Piv5 as oncolytic agent
PL2812431T3 (en) 2012-02-09 2020-02-28 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
CN103773803A (en) * 2014-01-23 2014-05-07 中国农业科学院特产研究所 Recombined cattle parainfluenza carrier for expressing protein VP1 of porcine O type foot-and-mouth disease virus
US11273214B2 (en) 2017-05-29 2022-03-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant chimeric bovine/human parainfluenza virus 3 expressing RSV G and its use
JP2021528972A (en) * 2018-06-27 2021-10-28 メディカゴ インコーポレイテッド Influenza virus hemagglutinin mutant
CN112771619A (en) * 2018-08-28 2021-05-07 皇家飞利浦有限公司 Method for evaluating the basis of genomic alignments
JP7656331B2 (en) * 2019-03-25 2025-04-03 ベイラー カレッジ オブ メディスン T cells specific for multiple respiratory viral antigens and methods for producing and using same in therapy
CN113462656B (en) * 2021-03-24 2022-09-30 兰州生物制品研究所有限责任公司 Human three-type parainfluenza virus cold-adaptation temperature-sensitive strain and application thereof
CN113999292B (en) * 2021-10-27 2023-05-26 中国农业大学 Polypeptide inhibitors targeting respiratory viruses
WO2023227758A1 (en) 2022-05-25 2023-11-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccine with reduced anti-vector antigenicity
WO2025106787A1 (en) 2023-11-17 2025-05-22 Sanofi Pasteur Inc. Trehalose vaccine formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9809456B1 (en) * 1997-05-23 2011-06-28 isolated polynucleotide molecule, cell-free or cell-free composition, infectious, attenuated and immunogenic piv particle, and, immunogenic composition.
CA2378661A1 (en) * 1999-07-09 2001-01-18 Alexander C. Schmidt Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines

Also Published As

Publication number Publication date
JP4795597B2 (en) 2011-10-19
CN1347453A (en) 2002-05-01
EP1179054A2 (en) 2002-02-13
WO2001042445A3 (en) 2001-11-29
AU785148B2 (en) 2006-10-05
AU2073101A (en) 2001-06-18
CA2362685A1 (en) 2001-06-14
JP2003516148A (en) 2003-05-13
MXPA01008108A (en) 2004-11-12
WO2001042445A2 (en) 2001-06-14
CN102766605A (en) 2012-11-07

Similar Documents

Publication Publication Date Title
IL144831A0 (en) USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS
ATE296040T1 (en) AIR-PERMEABLE CLOTHING TO IMPROVE THE COMFORT OF THE HUMAN BODY
AU2001281309A1 (en) The use of c3-c5 monosaccharides to protect keratinous fibers
GR1002767B (en) Insecticidal composition for treating and protecting domestic an
AU3947301A (en) The use of plant extracts and sugars to protect keratinous tissue
BR9710740A (en) Polynucleotide vaccine formula against respiratory and reproductive diseases of pigs
ATE236186T1 (en) L-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B AND EPSTEIN BAR VIRUS
SI0831921T1 (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
IS5191A (en) Antimicrobial barrier and treatment of the erosion virus and other human infectious diseases
HUP0301444A3 (en) The use of ribavirin-pegylated interferon alfa for the preparation of pharmaceutical compositions for the treatment of hcv infection
EP1434873A4 (en) Genotyping kit for diagnosis of human papilloma virus infection
ID27867A (en) OBJECTS OF ABSORPTION MAY BE DISPOSED TO THE BODY TO HAVE AN ADDITIONAL CUTTING ACCORDING TO THE BODY ANATOMY
EP1357940A4 (en) TREATMENT OF HEPATITIS B VIRUS
AU2678499A (en) Use of deprenyl compounds to treat viral infections and reduce tissue damage associated therewith
DE10084499T1 (en) Absorbent tissue to improve the skin's protective layer
GB9912639D0 (en) Improvements in and relating to treatment of respiratory conditions
BR9706938A (en) Compound use of the same pharmaceutical formulation and processes to produce the compound and for the treatment or prevention of symptoms or effects of a viral infection in an infected mammal including a human
EE200300502A (en) Use of cationic dextran derivatives to protect dose limiting organs
DE10075036I1 (en) Vaccine and diagnostic agent for the swine cholera virus
HUP0101410A2 (en) Elastic member and disposable garment having improved fitness to body during entire use
DK1049480T3 (en) Antiviral agent of plant origin
ITMI913493A0 (en) DEVICE FOR DISINFECTION OR IMMUNIZATION OF AREAS OF THE HUMAN BODY EXPOSED TO CONTAGION BY GERMS, BACTERIA AND VIRUSES
IL151033A0 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
DE59810175D1 (en) COMBINATION OF PHYSIOLOGICAL ACTIVE SUBSTANCES TO PROMOTE THE DEFENSE PERFORMANCE OF THE SKIN AGAINST NOX
NO970185D0 (en) Use of (S) -adenosyl-L-methionine (SAMe) and its physiologically compatible salts for the treatment of reperfusion injury triggered by temporal-focal ischemia